Cardiovascular

FDA changes to heparin labels aimed to reduce errors

On Dec. 6, the U.S. Food and Drug Administration (FDA) announced changes in requirements for heparin labels. This label change will require manufacturers of Heparin Lock Flush Solution, USP and Heparin Sodium Injection, USP to clearly state the strength of the entire container of the medication followed by how much of the medication is in 1 mL. The change will eliminate the need for healthcare professionals to calculate the total amount of heparin medication in a product containing more than 1 mL, which should reduce the risk of errors. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares